Sangamo Therapeutics, Inc
ST-503
chronic neuropathic pain
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ST-503 for chronic neuropathic pain around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“In December, the FDA granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain.”